Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Denosumab (Primary)
- Indications Advanced breast cancer; Bone metastases; Prostate cancer
- Focus Adverse reactions; Registrational
- Sponsors Amgen; Daiichi Sankyo Company
- 01 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 01 Dec 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 03 Feb 2016 Planned End Date changed from 1 Jun 2017 to 1 Dec 2016 as reported by ClinicalTrials.gov record.